Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients

Using a biomarker and investigational diagnostic, Roche has initiated a Phase II clinical trial of an amyloid-beta peptide antibody, gantenerumab, in patients with only mild cognitive deficits.